PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Disease

Small Cell Lung Cancer Extensive Stage

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · PHASE 1/2 TRIAL

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

ClinicalTrials.gov

This is a clinical trial registry record describing a Phase 1/2 study that is actively recruiting with no results yet posted; it represents early-stage evaluation of a novel combination therapy.

Preliminaryquaratusugene ozeplasmid Atezolizumab Small Cell Lung Cancer Extensive Stage

Reported

Planned enrollment62

Phase 1 primary outcomeMaximum Tolerated Dose (MTD)/Recommended Ph…

Phase 2 primary outcomeProgression-Free Survival Rate (PFSR) at 18…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support